All Stories

  1. Implementation of Synoptic Reports in Enhancing Documentation Practices in Pediatric Surgical Oncology: A Systematic Review
  2. Opioid-sparing utility of subcutaneous analgesia systems in pediatric oncology patients following major tumor resection surgery: a matched case-control study
  3. H3F3A K36M-mutant Epithelioid Neoplasm: A Report of Two Novel Cases of a Non-chondrogenic H3K36-altered Mesenchymal Tumor
  4. Surgical Practices in the Management of Pediatric Renal Tumors in Low‐ and Middle‐Income Countries in the Asia Pacific Region
  5. Introduction
  6. Skeletal Muscle Tumours
  7. Desmoplastic Small Round Cell Tumour
  8. Inter-Ethnic Variations in the Clinical, Pathological, and Molecular Characteristics of Wilms Tumor
  9. Childhood cancer surgery in low‐ and middle‐income countries
  10. Abstract P61: Distinct Roles of BRD4 Isoforms in Tumor Progression and Metastasis in Embryonal Rhabdomyosarcoma
  11. Systematic Lymphatic Repair for Reduction of Postoperative Lymphatic Leak Following Neuroblastoma Resection
  12. BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma
  13. Data from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  14. Data from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  15. FIGURE 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  16. FIGURE 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  17. FIGURE 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  18. FIGURE 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  19. FIGURE 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  20. FIGURE 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  21. FIGURE 4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  22. FIGURE 4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  23. FIGURE 5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  24. FIGURE 5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  25. Figure S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  26. Figure S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  27. Figure S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  28. Figure S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  29. Figure S3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  30. Figure S3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  31. Figure S4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  32. Figure S4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  33. Figure S5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  34. Figure S5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  35. Figure S6 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  36. Figure S6 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  37. Figure S7 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  38. Figure S7 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  39. Supplementary Data - raw Western blot images from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  40. Supplementary Data - raw Western blot images from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  41. Supplementary Data 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  42. Supplementary Data 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  43. Supplementary Data 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  44. Supplementary Data 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  45. Supplementary Data 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  46. Supplementary Data 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  47. Supplementary Methods from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  48. Supplementary Methods from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  49. Table S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  50. Table S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  51. Table S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  52. Table S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma
  53. Targeted degradation of XIAP is sufficient and specific to induce apoptosis in MYCN-overexpressing high-risk neuroblastoma
  54. Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody
  55. Solitary pulmonary nodule in an early adolescent
  56. #299 Alveolar soft part sarcoma of the cervix mimicking a cervical fibroid: a diagnostic and management challenge
  57. BRD4 isoforms have distinct roles in tumor progression and metastasis in embryonal rhabdomyosarcoma
  58. Aggressive Pursuit of No Evidence of Disease Status in Hepatoblastoma Improves Survival: An Observational Study
  59. Targeting RNA Polymerase I Transcription Activity in Osteosarcoma: Pre-Clinical Molecular and Animal Treatment Studies
  60. Implementation of Multidisciplinary Teams for the Treatment of Childhood Cancer
  61. Mitochondrial calcium uptake regulates tumour progression in embryonal rhabdomyosarcoma
  62. Impact of treatment refusal and abandonment on survival outcomes in pediatric osteosarcoma in Southeast Asia: A multicenter study
  63. Postoperative Rather Than Preoperative Neutropenia Is Associated With Early Catheter-related Bloodstream Infections in Newly Diagnosed Pediatric Cancer Patients
  64. Subcutaneous panniculitis‐like T‐cell lymphomas with homozygous inheritance of HAVCR2 mutations in Vietnamese pedigrees
  65. Gastrointestinal and oncologic outcomes of pediatric gastrointestinal lymphoma following upfront resection or biopsy of bowel masses
  66. Rhabdomyosarcoma
  67. Pediatric Solid Tumor Care and Multidisciplinary Tumor Boards in Low- and Middle-Income Countries in Southeast Asia
  68. Neuroblastoma patient‐derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response
  69. Massively parallel single-molecule telomere length measurement with digital real-time PCR
  70. Larotrectinib followed by selitrectinib in a novel DCTN1–NTRK1 fusion undifferentiated pleomorphic sarcoma
  71. Rhabdomyosarcoma
  72. Posterior retroperitoneoscopic adrenalectomy for pediatric adrenal tumors
  73. Destined to Die: Apoptosis and Pediatric Cancers
  74. Retroperitoneal tumors and congenital variations in vascular anatomy of retroperitoneal great vessels
  75. Evaluation of a Novel Bony Landmark-Based Method for Teaching Percutaneous Insertion of Subclavian Venous Catheters in Pediatric Patients
  76. Primary Adrenal Angiomatoid Fibrous Histiocytoma With Novel EWSR1-ATF1 Gene Fusion Exon–Exon Breakpoint
  77. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations
  78. Soft Tissue Sarcomas
  79. Clinical, pathological and loss of heterozygosity differences in Wilms tumors between Asian and non-Asian children
  80. Clinical relevance of screening checklists for detecting cancer predisposition syndromes in Asian childhood tumours
  81. Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR-CCNB3 gene fusion
  82. Clinical management of pheochromocytoma and paraganglioma in Singapore: missed opportunities for genetic testing
  83. Operative and Immediate Postoperative Differences Between Traditional Multiport and Reduced Port Laparoscopic Total Splenectomy in Pediatric Patients
  84. Management of a Kaposiform haemangioendothelioma of the kidney with Kasabach-Meritt phenomenon without chemotherapy
  85. Re: External validation of the Paediatric Risk of Malignancy Index
  86. Initial diagnostic management of pediatric bone tumors
  87. XAF1 promotes neuroblastoma tumor suppression and is required for KIF1Bβ-mediated apoptosis
  88. Thyroglossal duct cyst carcinoma: diagnostic and management considerations in a 15-year-old with a large submental mass
  89. Novel Karyotypes and Cyclin D1 Immunoreactivity in Clear Cell Sarcoma of the Kidney
  90. Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma
  91. Long-term physiologic and oncologic outcomes of inferior vena cava thrombosis in pediatric malignant abdominal tumors
  92. Safety and diagnostic accuracy of tumor biopsies in children with cancer
  93. An Approach to Renal Masses in Pediatrics
  94. Influence of bony resection margins and surgicopathological factors on outcomes in limb-sparing surgery for extremity osteosarcoma
  95. Targeting the DNA Repair Pathway in Ewing Sarcoma
  96. The Role of Thoracoscopic Surgery in Pediatric Oncology
  97. Minimally invasive surgery in the management of abdominal tumors in children
  98. Management of Local Recurrence of Pediatric Osteosarcoma Following Limb-Sparing Surgery
  99. Diagnostic accuracy of preoperative alpha-fetoprotein as an ovarian tumor marker in children and adolescents: not as good as we thought?
  100. Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration
  101. Pediatric risk of malignancy index for preoperative evaluation of childhood ovarian tumors
  102. Diagnostic delay in pediatric solid tumors: A population based study on determinants and impact on outcomes
  103. Corrigenda
  104. Gene Expression of TRK Neurotrophin Receptors in Advanced Neuroblastomas in Singapore—A Pilot Study
  105. Neonatal Ovarian Cysts: Role of Sonography in Diagnosing Torsion
  106. Delays in Diagnosis of Pediatric Solid Tumors in Singapore
  107. Port-A-Cath insertions in acute leukemia: does thrombocytopenia affect morbidity?
  108. Port-A-Cath Insertions in Acute Leukaemia and Childhood Malignancies
  109. Neonatal intestinal volvulus due to a persistent right vitelline artery